Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 07 2022
Historique:
received: 30 09 2021
revised: 23 02 2022
accepted: 02 03 2022
pubmed: 13 3 2022
medline: 7 7 2022
entrez: 12 3 2022
Statut: ppublish

Résumé

Childhood cancer is rare, and treatment is frequently associated with long-term morbidity. Disparities in survival and long-term side effects encourage the establishment of networks to increase access to complex organ-conservative strategies, such as brachytherapy. We report our experience of an international cooperation model in childhood cancers. We examined the outcome of all children referred to our center from national or international networks to be treated according to a multimodal organ-conservative approach, including brachytherapy. We identified 305 patients whose median age at diagnosis was 2.2 years (range, 1.4 months to 17.2 years). Among these patients, 99 (32.4%) were treated between 2015 and 2020; 172 (56.4%) were referred from national centers; and 133 (43.6%) were international patients from 31 countries (mainly Europe). Also, 263 patients were referred for primary treatment and 42 patients were referred for salvage treatment. Genitourinary tumors were the most frequent sites, with 56.4% bladder/prostate rhabdomyosarcoma and 28.5% gynecologic tumors. In addition to brachytherapy, local treatment consisted of partial tumor resection in 207 patients (67.9%), and 39 patients (13%) had additional external radiation therapy. Median follow-up was 58 months (range, 1 month to 48 years), 93 months for national patients, and 37 months for international patients (P < .0001). Five-year local control, disease-free survival, and overall survival rates were 90.8% (95% confidence interval [CI], 87.3%-94.4%), 84.4% (95% CI, 80.1%-89.0%), and 93.3% (95% CI, 90.1%-96.5%), respectively. Patients referred for salvage treatment had poorer disease-free survival (P < .01). Implementation of image guided pulse-dose-rate brachytherapy was associated with better local control among patients with rhabdomyosarcoma referred for primary treatment (hazard ratio, 9.72; 95% CI, 1.24-71.0). At last follow-up, 16.7% patients had long-term severe treatment-related complications, and 2 patients (0.7%) had developed second malignancy. This retrospective series shows the feasibility of a multinational referral network for brachytherapy allowing high patient numbers in rare pediatric cancers. High local control probability and acceptable late severe complication probability could be achieved despite very challenging situations. This cooperation model could serve as a basis for generating international reference networks for high-tech radiation such as brachytherapy to increase treatment care opportunities and cure probability.

Identifiants

pubmed: 35278672
pii: S0360-3016(22)00196-1
doi: 10.1016/j.ijrobp.2022.03.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

602-613

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Cyrus Chargari (C)

Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: cyrus.chargari@gustaveroussy.fr.

Christine Haie-Meder (C)

Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Sophie Espenel (S)

Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Max-Adrien Garcia (MA)

Centre Hygée, Saint Etienne, France.

Myriam Ben-Arush (M)

Ruth Rappaport Children's Hospital, Haifa, Israel.

Stéphanie Bolle (S)

Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Anna Borjesson (A)

Department of Pediatric Surgery, Lund University Hospital, Lund, Sweden.

Maja Cesen (M)

University Children's Hospital Ljubljana, Ljubljana, Slovenia.

Rita Costa Lago (RC)

Radiation Oncology Department, Centro Hospitalar Universitário de São João, Porto, Portugal.

Anne-Sophie Defachelles (AS)

Pediatric Oncology, Centre Oscar Lambret, Lille, France.

Barbara De Moerloose (B)

Department of Pediatric Hemato-Oncology, Ghent University Hospital, Ghent, Belgium.

Christine Devalck (C)

Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.

Pernille Edslev (P)

Child and Adolescent Health, Division for Hematology and Oncology, Aarhus University Hospital, Aarhus, Denmark.

Nuno Jorge Farinha (NJ)

Pediatric Oncology Department, Centro Hospitalar Universitário de São João, Porto, Portugal.

Nadine Francotte (N)

Service Interhospitalier Universitaire d'Hématologie et d'Oncologie Pédiatrique Liégeois, Liège, Belgium.

Heidi Glosli (H)

Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

Sebastien Gouy (S)

Gynecological Surgery, Gustave Roussy Cancer Campus, Villejuif, France.

Gabriela Guillen Burrieza (GG)

Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Sylvie Helfre (S)

Radiation Oncology, Institut Curie, Paris, France.

Sabine Irtan (S)

Sorbonne Université, Visceral and Neonatal Pediatric Surgery, Centre Hospitalier Universitaire Armand Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France.

Antonis Kattamis (A)

Division of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece.

Ana Lacerda (A)

Pediatric Oncology, Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.

Antonin Levy (A)

Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Lisa Lyngsie Hjalgrim (LL)

Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.

Ludovic Mansuy (L)

Pediatric Oncology, Centre Hospitalier Universitaire de Nancy, Nancy, France.

Eric Mascard (E)

Pediatric Surgery, Centre Hospitalier Universitaire Necker, Paris, France.

Salma Moalla (S)

Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France.

Daniel Orbach (D)

SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Paris Sciences et Lettres University, Institut Curie, Paris, France.

Cormac Owens (C)

National Pediatric Oncology Unit, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland.

Pascale Philippe-Chomette (P)

Pediatric Surgery, Hôpital Universitaire Robert-Debré, Assistance Publique de Hôpitaux de Paris, Paris, France.

Barry Pizer (B)

Department of Paediatric Oncology, Alder Hey Children's Hospital, Liverpool, United Kingdom.

Claire Pluchart (C)

Service d'Oncologie Pédiatrique, Centre Hospitalier Universitaire de Reims, Reims, France.

Marleen Renard (M)

Kinderhemato-Oncologie, University Hospital, Leuven, Belgium.

Anne Gro Wesenberg Rognlien (AGW)

Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

Angélique Rome (A)

Pediatric Oncology, Hôpital La Timone, Marseille, France.

Sabine Sarnacki (S)

Pediatric Surgery, Centre Hospitalier Universitaire Necker, Paris, France.

Akmal Safwat (A)

Oncology Department and Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.

Amalia Schiavetti (A)

Pediatric Oncology Unit, Sapienza University of Rome, Rome, Italy.

Jill Serre (J)

Centre Hospitalier Regional et Universitaire Clocheville, Tours, France.

Cécile Verite (C)

Pediatric Oncology, Groupe Hospitalier Pellegrin Hôpital des Enfants, Bordeaux, France.

Nicolas Von Der Weid (NV)

Pediatric Oncology, Universitäts-Kinderspital Beider Basel, University of Basel, Basel, Switzerland.

Mariusz Wysocki (M)

Department of Pediatric Hematology and Oncology, Dr Antoni Jurasz Memorial University Hospital, Bydgoszcz, Poland.

Dominique Valteay-Couanet (D)

Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Eric Deutsch (E)

Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Véronique Minard-Colin (V)

Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Hélène Martelli (H)

Paris-Saclay University, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Department of Pediatric Surgery, Le Kremlin Bicêtre, France.

Florent Guérin (F)

Paris-Saclay University, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Department of Pediatric Surgery, Le Kremlin Bicêtre, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH